Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at better outcomes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Menoufia University
• Treatments: Fluorouracil; Gemcitabine

Criteria

Inclusion Criteria:

• Histopathological evidence of adenocarcinoma of the pancreas

• Radiological proof of metastatic disease as defined by AJCC

Exclusion Criteria:

• patients with poor performance status (ECOG 4)

• patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 mg/dl

• patients with end stage renal disease who are under regular dialysis

• other histologies of pancreatic cancer

• irresectable pancreatic cancer if not metatatic